Epidemiology, pathogenesis, molecular characteristics, classification and prognosis of the diffuse large B-cell lymphoma

##plugins.themes.bootstrap3.article.main##

С. М. Гайдукова
С. В. Видиборець
Ю. Ю. Попович

Abstract

The article presents the results of systematic review of the available literature sources (search in JAMA, Scholar, NCBI, Cochrane Library and PubMed databases, 2007–2018 has been performed) about the epidemiology, pathogenesis, molecular characteristics, classification and risk factors of the epidemiology, pathogenesis, molecular characteristics, classification and risk factors of the diffuse large B-cell lymphoma (DLBCL).

##plugins.themes.bootstrap3.article.details##

How to Cite
Гайдукова, С. М., Видиборець, С. В., & Попович, Ю. Ю. (2018). Epidemiology, pathogenesis, molecular characteristics, classification and prognosis of the diffuse large B-cell lymphoma. Family Medicine, (5), 36–40. https://doi.org/10.30841/2307-5112.5.2018.165327
Section
Topical issues
Author Biographies

С. М. Гайдукова, P.L. Shupyk National Medical Academy of Postgraduate Education

Svitlana M. Gaidukova,

Department of Haematology and Transfusiology

С. В. Видиборець, P.L. Shupyk National Medical Academy of Postgraduate Education

Stanislav V. Vydyborets,

Head of Department of Haematology and Transfusiology

Ю. Ю. Попович, Uzhhorod National University

Yurii Yu. Popovich,

Department of Hospital Therapy

References

Abu Shanab A.A. Salah. Modern advance for B-lymphopoiesis / Abushanab A.A. Salah // Сімейна медицина / Family medicine. – 2015. – no. 3(59). – P. 246–247.

Adams H. Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms / Adams H., Liebisch P., Schmid P. et al. // Appl. Immunohistochem. Mol. Morphol. – 2009. – Vol. 17. – P. 96–101. https://doi.org/10.1097/PAI.0b013e3181845ef4

Akyurek N. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab / Akyurek N., Uner A., Benekli M. et al. // Cancer. – 2011. – Vol. 118. – P. 4173–4183. https://doi.org/10.1002/cncr.27396

A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project // N Engl. J. Med. – 1993. – Vol. 329. – P. 987–994. https://doi.org/10.1056/NEJM199309303291402

Bakhshi A. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18 / Bakhshi A. Jensen J.P., Goldman P. et al. // Cell. – 1985. – Vol. 41. – P. 899–906. https://doi.org/10.1016/S0092-8674(85)80070-2

Barrans S. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab / Barrans S. Crouch S., Smith A. et al. // J Clin. Oncol. – 2010. – Vol. 28. – P. 3360–3365. https://doi.org/10.1200/JCO.2009.26.3947

Bergsagel P.L. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma / Bergsagel P.L. Chesi M., Nardini E. et al. // Proc Natl. Acad. Sci. U.S.A. – 1996. – Vol. 93. – P. 13931–13936. https://doi.org/10.1073/pnas.93.24.13931

Campo E. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications / Campo E., Swerdlow SH., Harris NL. et al. // Blood. – 2011. – Vol. 117. – P. 5019–5032. https://doi.org/10.1182/blood-2011-01-293050

Choi W.W. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy / Choi W.W., Weisenburger D.D., Greiner T.C. et al. // Clin. Cancer. Res. – 2009. – Vol. 15. – P. 5494–5502. https://doi.org/10.1158/1078-0432.CCR-09-0113

Colleoni G.W. Linfomas não-hodgkin: aspectos clínicos, prognósticos e terapêuticos na era do rituximabe / Colleoni G.W., Inaoka R.J. // Diálogo Científico. – 2007. – Vol. (Nov/Dec). – P. 19–22.

Compagno M. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma / Compagno M., Lim W.K., Grunn A. et al. // Nature. – 2009. – Vol. 459. – P. 717–721. https://doi.org/10.1038/nature07968

Davis R.E. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells / Davis RE., Brown KD., Siebenlist U. et al. // J Exp. Med. – 2001. – Vol. 194. – P. 1861–1874. https://doi.org/10.1084/jem.194.12.1861

Davis R.E. Chronic active B-cellreceptor signalling in diffuse large B-cell lymphoma / Davis R.E., Ngo VN., Lenz G. et al. // Nature. – 2010. – Vol. 463. – P. 88–92. https://doi.org/10.1038/nature08638

Friedberg J.W. Rituximab for early stage diffuse large B-cell lymphoma // Lancet Oncol. – 2006. – Vol. 7 (5). – P. 357–359. https://doi.org/10.1016/S1470-2045(06)70668-4

Fugmann S.D. The RAG proteins and V(D)J recombination: Complexes, ends, and transposition / Fugmann S.D., Lee A.I., Shockett P.E. et al. // Annu. Rev. Immunol. – 2000. – Vol. 18. – P. 495–527. https://doi.org/10.1146/annurev.immunol.18.1.495

Gomez-Abad C. PIM inhibition as a rational therapeutic approach in diffuse large B cell lymphoma / Gomez-Abad C., Pisonero H., Blanco-Aparicio C. // Ann. Oncol. – 2011. – Vol. 22. Abstract 154. https://doi.org/10.1093/annonc/mdr211

Gonçalves E.M. Linfomas difusos de grandes células B – factores de prognóstico clínicos [dissertation] // Porto: Universidade do Porto. – 1999. PDF

Goossens T. Frequent occurrence of deletions and duplications during somatic hypermutation: Implications for oncogene translocations and heavy chain disease / Goossens T., Klein U., Kuppers R. // Proc Natl Acad Sci USA. – 1998. – Vol. 95. – P. 2463–2468. https://doi.org/10.1073/pnas.95.5.2463

Hans C.P. Confirmation of the molecular classification of diffuse large Bcell lymphoma by immunohistochemistry using a tissue microarray / Hans C.P., Weisenburger D.D., Greiner T.C. et al. // Blood. – 2004. – Vol. 103. – P. 275–282. https://doi.org/10.1182/blood-2003-05-1545

Hill B.T. Cell of origin determination in diffuse large b-cell lymphoma: Performance of immunohistochemical (IHC) algorithms and ability to predict outcome / Hill B.T., Collie A.M.B., Radivoyevitch T. et al. // Blood. – 2011. – Vol. 118 (suppl 21):Abstract. 950. Full text

Iqbal J. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab / Iqbal J., Meyer P.N., Smith L.M. et al. // Clin. Cancer Res. – 2011. – Vol. 17. – P. 7785–7795. https://doi.org/10.1158/1078-0432.CCR-11-0267

Joos S. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene / Joos S., Otano-Joos M.I., Ziegler S. et al. // Blood. – 1996. – Vol. 87. – P. 1571–1578. PDF

Kato M. Frequent inactivation of A20 in B-cell lymphomas / Kato M., Sanada M., Kato I. et al. // Nature. – 2009. – Vol. 459. – P. 712–716. https://doi.org/10.1038/nature07969

Klapper W. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL) / Klapper W., Stoecklein H., Zeynalova S. et al. // Leukemia. – 2008. – Vol. 22. – P. 2226–2229. https://doi.org/10.1038/leu.2008.230

Kraus M. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer / Kraus M., Alimzhanov M.B., Rajewsky N. et al. // Cell. – 2004. –Vol. 117. – P. 787–800. https://doi.org/10.1016/j.cell.2004.05.014

Lam L.T. Small molecule inhibitors of I kappa B kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling / Lam L.T., Davis R.E, Pierce J. et al. // Clin. Cancer Res. – 2005. – Vol. 11. – P. 28–40.

Lam L.T. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma / Lam L.T., Wright G., Davis R.E. et al. // Blood. – 2008. – Vol. 111. – P. 3701–3713. https://doi.org/10.1182/blood-2007-09-111948

Lenz G. Aggressive lymphomas / Lenz G., Staudt L.M. // N. Engl. J. Med. – 2010. – Vol. 362. – P. 1417–1429. https://doi.org/10.1056/NEJMra0807082

Liu M. Two levels of protection for the B cell genome during somatic hypermutation / Liu M., Duke J.L., Richter D.J. et al. // Nature. – 2008. – Vol. 451. – P. 841–845. https://doi.org/10.1038/nature06547

Lohr J.G. Discovery and prioritization of somatic mutations in diffuse large Bcell lymphoma (DLBCL) by whole-exome sequencing / Lohr J.G., Stojanov P., Lawrence M.S. et al. // Proc. Natl. Acad. Sci. U.S.A. – 2012. – Vol. 109. – P. 3879–3884. https://doi.org/10.1073/pnas.1121343109

Lymphomas 2018. ESMO Pocket Guidelines. European Society by Medical Oncology, 191 p.

Manis J. P. Mechanism and control of class-switch recombination / Manis J.P., Tian M., Alt F.W. // Trends Immunol. – 2002. – Vol. 23. – P. 31–39. https://doi.org/10.1016/S1471-4906(01)02111-1

Meyer P.N. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large Bcell lymphoma treated with rituximab. / Meyer P.N., Fu K., Greiner T.C. et al. // J. Clin. Oncol. – 2011. – Vol. 29. – P. 200–207. https://doi.org/10.1200/JCO.2010.30.0368

Migliazza A. Frequent somatic hypermutation of the 5-noncoding region of the BCL6 gene in B-cell lymphoma / Migliazza A., Martinotti S., Chen W. et al. // Proc. Natl. Acad. Sci. U. S. A. – 1995. – Vol. 92. – P. 12520–12524. https://doi.org/10.1073/pnas.92.26.12520

Morin R.D. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma / Morin R.D., Mendez-Lago M., Mungall A.J. et al. // Nature. – 2011. – Vol. 476. – P. 298–303. https://doi.org/10.1038/nature10351

Muramatsu M. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme / Muramatsu M., Kinoshita K., Fagarasan S. et al // Cell. – 2000. – Vol. 102. – P. 553–563. https://doi.org/10.1016/S0092-8674(00)00078-7

Nardini E. Detection of aberrant isotype switch recombination in low-grade and high-grade gastric MALT lymphomas / Nardini E., Aiello A., Giardini R. et al. // Blood. – 2000. – Vol. 95. – P. 1032–1038. PDF

Ngo V.N. A loss-of-function RNA interference screen for molecular targets in cancer / Ngo V.N., Davis R.E., Lamy L. et al. // Nature. – 2006. – Vol. 441. – P. 106–110. https://doi.org/10.1038/nature04687

Nogai H. Pathogenesis of Non-Hodgkin’s Lymphoma / Nogai H., Dorken B., Lenz G. // J. Clin. Oncol. – 2011. – Vol. 29. – P. 1803–1811. https://doi.org/10.1200/JCO.2010.33.3252

Obermann E.C. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma / Obermann E.C., Csato M., Dirnhofer S. et al. // J. Clin. Pathol. – 2009. – Vol. 62. – P. 903–907. https://doi.org/10.1136/jcp.2009.066597

Ott M.M. The Hans classificator does not predict outcome in diffuse large B cell lymphoma in a large multicenter retrospective analysis of R-CHOP treated patients / Ott M.M., Horn H., Kaufmann M. et al. // Leuk Res. – 2012. – Vol. 36. – P. 544–545. https://doi.org/10.1016/j.leukres.2012.01.022

Ott G. Immunoblastic morphology but not the immunohistochemical GCB / nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL / Ott G., Ziepert M., Klapper W. et al. // Blood. – 2010. – Vol. 116. – P. 4916–4925. https://doi.org/10.1182/blood-2010-03-276766

Pasqualucci L. Inactivating mutations of acetyltransferase genes in B-cell lymphoma / Pasqualucci L., Dominguez-Sola D., Chiarenza A. et al. // Nature. – 2011. – Vol. 471. – P. 189–195. https://dx.doi.org/10.1038%2Fnature09730

Pasqualucci L. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas / Pasqualucci L., Neumeister P., Goossens T. et al. // Nature. – 2001. – Vol. 412. – P. 341–346. https://doi.org/10.1038/35085588

Pasqualucci L. Analysis of the coding genome of diffuse large B-cell lymphoma / Pasqualucci L., Trifonov V., Fabbri G. et al. // Nat Genet. – 2011. – Vol. 43. – P. 830–837. https://doi.org/10.1038/ng.892

Pui C.H. Central nervous system disease in hematologic malignancies: historical perspective and practical applications / C.H. Pui, E. Thiel // Semin. Oncol. – 2009. – Vol. 36. – P. S2–S16. https://doi.org/10.1053/j.seminoncol.2009.05.002

Rajewsky K. Clonal selection and learning in the antibody system // Nature. – 1996. – Vol. 381. – P. 751–758. https://doi.org/10.1038/381751a0

Ramiro A.R. AID is required for cmyc/IgH chromosome translocations in vivo / Ramiro A.R., Jankovic M., Eisenreich T. et al. // Cell. – 2004. – Vol. 118. – P. 431–438. https://doi.org/10.1016/j.cell.2004.08.006

Ryan R.J. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas / Ryan R.J., Nitta M., Borger D. et al. // PLoS One. – 2011. – Vol. 6:e28585. https://doi.org/10.1371/journal.pone.0028585

Rosenwald A. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma / Rosenwald A., Wright G., Chan W.C. et al. // N. Engl. J. Med. –2002. – Vol. 346. – P. 1937–1947. https://doi.org/10.1056/NEJMoa012914

Rosenwald A. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma / Rosenwald A., Wright G., Leroy K. et al. // J. Exp. Med. – 2003. – Vol. 198. – P. 851–862. https://doi.org/10.1084/jem.20031074

Salah A.A. Abushanab. Analysis of Tp53 gene polymorphic variants in predicting of toxic complication in non-Hodgkin’s lymphoma treatment / Salah A.A. Abushanab, Vydyborets S., Gorovenko N., Gartovska I., Kyriachenko S., Rossokha Z. // Hematology. Transfusiology. Eastern Europe. – 2016. – Vol. 2, no. 1. – P. 155–165.

Salah A.A. Abushanab. Evaluation of clinic and laboratory parameters and genetic markers in predicting of toxic complications in treatment of patients with non-Hodgkin’s lymphoma / Salah A.A. Abushanab, Vydyborets S., Gorovenko N., Gartovska I., Kyriachenko S., Rossokha Z. // Hematology. Transfusiology. Eastern Europe. – 2016. – Vol. 2, no. 2. – P. 198–206.

Salah A.A. Abushanab. The influence of genetic factors on the development of different clinical manifestations of toxicity in patients with non-Hodgkin’s lymphoma / Salah A.A. Abushanab, Vydyborets S., Gorovenko N., Gartovska I., Kyriachenko S., Rossokha Z. // Hematology. Transfusiology. Eastern Europe. – 2015. –no. 3 (03). – P. 48–61.

Schmitz R. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma / Schmitz R., Hansmann ML., Bohle V. et al. // J. Exp. Med. – 2009. – Vol. 206. – P. 981–989. https://doi.org/10.1084/jem.20090528

Shahi P.K. Linfoma B difuso de células grandes / Shahi P.K., Manga G.P. // Med. Clin. (Barc). – 2006. – Vol. 127 (1). – P. 17–21. https://doi.org/10.1157/13089865

Song M.K. Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP / Song M.K., Chung J.S., Shin D.H. et al. // Leuk. Lymphoma. – 2009. – Vol. 50. – P. 54–61. https://doi.org/10.1080/10428190802626616

Swerdlow S.H. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of Tumours). // World Health Organization. – 2008. – 4th edition.

Thieblemont C. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A bio-CORAL study / Thieblemont C., Briere J., Mounier N. et al. // J. Clin. Oncol. – 2011. – Vol. 29. – P. 4079–4087. https://doi.org/10.1200/JCO.2011.35.4423

Turner J.J. WHO non-Hodgkin’s lymphoma classification by criterionbased report review followed by targeted pathology review: an effective strategy for epidemiology studies / Turner J.J., Hughes A.M., Kricker A. et al. // Cancer Epidemiol. Biomarkers Prev. – 2005. – Vol. 14. – P. 2213–2219. https://doi.org/10.1158/1055-9965.EPI-05-0358

Tzankov A. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. / Tzankov A., Zlobec I., Went P. et al. // Leuk. Lymphoma. – 2010. – Vol. 51. – P. 199–212. https://doi.org/10.3109/10428190903370338

Visco C. The t(14;18)(q32;q21) characterizes a subset of patients with diffuse large-B cell lymphoma of germinal center origin with poor outcome: Report from the international DLBCL rituximab-CHOP consortium program study / Visco C., Tzankov A., Xu-Monette Z.Y. et al. // Blood. – 2011. – Vol. 118. – Abstract 949. Full text

Wang X. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas / Wang X., Li Z., Naganuma A. et al. // Proc. Natl. Acad. Sci. USA. – 2002. – Vol. 99. – P. 15018–15023. https://doi.org/10.1073/pnas.232581199

World Health Organization. Pathology and genetics of tumours of haematopoietic and lymphoid tissues // Lyon: International Agency for Research on Cancer. 2001.